5 mM peptide

IN THE CLAIMS

Ι,

Please cancel claims 1, 3, 11 - 13 and 16 - 28.

Please replace the following amended claims with a clean copy of said claims. A marked-up version is appended hereto as Appendix II.

2.(Once amended) A reduced allergenic variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of a cellulase, lipase, endoglucosidase H, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase and a protease and said polypeptide of interest comprises a T-cell epitope,

wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that one or more amino acid residues of the T-cell epitope are altered and wherein an allergenic immunogenic response produced by said variant in an individual is less than said allergenic immunogenic response produced by said polypeptide of interest.

- 5.(Once amended) The variant of claim 2, wherein said polypeptide of interest is not recognized by said individual as endogenous to said individual.
- 7.(Once amended) The variant of claim 2, wherein said T-cell epitope is altered with amino acid substitutions.
- 8.(Once amended) A reduced allergenic variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of a cellulase, lipase, endoglucosidase H, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase and a protease and said polypeptide of interest comprises a T-cell epitope,

wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that an allergenic immunogenic response produced by said variant in an individual is less than said allergenic immunogenic response produced by said polypeptide of interest, wherein said T-cell epitope is altered by having a terminal portion of said polypeptide of interest comprising said T-cell epitope replaced with a corresponding terminal portion of a homolog of

said polypeptide of interest wherein said homolog does not comprise a T-cell epitope identical to said replaced T-cell epitope.

14.(Twice amended) A cleaning composition, an animal feed composition, or a composition for treating a textile comprising the variant of claim 2.

Please add the following new claims

- 29. The variant of claim 2, wherein said polypeptide of interest is a cellulase.
- 30. The variant of claim 29, wherein the T-cell epitope of the polypeptide of interest corresponds to the amino acid sequence disclosed in SEQ ID NO. 222 or SEQ ID NO: 223.
- 31. The variant of claim 2, wherein said polypeptide of interest is a lipase.
- 32. The variant of claim 31, wherein the T-cell epitope of the polypeptide of interest corresponds to the amino acid sequence disclosed in SEQ ID NO: 225 or SEQ ID NO: 226.
- 33. The variant of claim 2, wherein said polypeptide of interest is an endoglucosidase H.
- 34. The variant of claim 33, wherein the T-cell epitope of the polypeptide of interest corresponds to the amino acid sequence disclosed in SEQ ID NO: 228.
- 35. A reduced allergenic variant of a protease of interest, wherein said protease of interest comprises a T-cell epitope and said protease of interest is altered by having a terminal portion of the protease comprising said T-cell epitope replaced with a corresponding terminal portion of a homolog of said protease of interest,

wherein said homolog does not comprise a T-cell epitope identical to the replaced T-cell epitope and wherein said variant produces a lessened allergenic response in an individual compared to the protease of interest.

36. The variant of claim 35, wherein the protease of interest is a subtilisin

- 37. The variant of claim 35, wherein the variant comprises the amino acid sequence of SEQ ID NO: 236.
- 38. A cleaning composition, an animal feed composition, a contact lens cleaning solution or a composition for treating a textile comprising the variant of claim 8.
- 39. A cosmetic care formulation for skin, hair or oral care comprising the variant of claim 2.
- 40. A cosmetic care formulation for skin, hair or oral care comprising the variant of claim 35.
- 41. A reduced allergenic variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of a cellulase, lipase, endoglucosidase H, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase and a protease and said polypeptide of interest comprises a T-cell epitope,

wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that at least two amino acid residues of the T-cell epitope are altered, and

wherein an allergenic immunogenic response produced by said variant is less in an individual than the allergenic immunogenic response produced by said polypeptide of interest.